Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24


51716 items
3:45 PM, Sep 17, 2018  |  BC Extra | Clinical News

argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in...
3:34 PM, Sep 17, 2018  |  BC Extra | Clinical News

Mersana gets green light to resume ADC trial, but new dosing may slow progress

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 seemingly in...
3:10 PM, Sep 17, 2018  |  BC Extra | Company News

Management tracks: Ultragenyx, Epizyme

Rare and ultra-rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) appointed Wladimir Hogenhuis as COO. Previously, he was SVP and general manager, specialty franchise at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Epizyme Inc. (NASDAQ:EPZM) said CBO Susan Graf will...
3:02 PM, Sep 17, 2018  |  BC Extra | Company News

United gets rights to Samumed's IPF compound

Samumed LLC (San Diego, Calif.) granted United Therapeutics Corp. (NASDAQ:UTHR) exclusive, U.S. and Canadian rights to idiopathic pulmonary fibrosis candidate SM04646, a Wnt signaling pathway inhibitor. Samumed will receive $10 million up front, and is eligible...
2:36 PM, Sep 17, 2018  |  BC Extra | Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
2:29 PM, Sep 17, 2018  |  BC Extra | Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
5:20 PM, Sep 14, 2018  |  BC Extra | Company News

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication. Teva...
4:41 PM, Sep 14, 2018  |  BC Extra | Politics & Policy

Congress to allocate additional $2 billion to NIH

Congress released a conference report Thursday calling for a $2 billion FY19 funding increase for NIH. The report represents a spending agreement between the Senate and the House of Representatives, and includes a FY19 budget...
4:33 PM, Sep 14, 2018  |  BC Extra | Financial News

Kleiner Perkins to split in two

Kleiner Perkins is splitting up its early stage and growth-stage investment teams. The firm will spin off its growth-stage team, which includes Mary Meeker, Mood Rowghani, Noah Knauf and Juliet de Baubigny, into an independent firm...
4:32 PM, Sep 14, 2018  |  BC Extra | Preclinical News

UCSD researchers identify mechanism, target in NASH

Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH), which could lead to a therapeutic approach and biomarkers of disease progression. Caspases are suspected targets...